A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I really need to stop outperforming stocks into drug launches. My last green thumb on Xenoport set me back rather severely in my quest for score leadership. In return for my faith I got 0.6M in quarterly Horizant revenues and yet another trial failure, this time with XP21279 in Parkinson's. Now, for a 46M enterprise value the company has a 20M quarterly burn, an sNDA for Horizant in post-herpetic neuropathy on June 9, and a phase III trial of arbaclofen in MS spasticity. Recently approved drugs for PHN haven't made much impact and I think Horizant is destined for the scrap heap. The arbaclofen phase III trial is still in the enrollment stages and that candidate has already failed in two phase II trial is GERD.
The solution? Abandon the Xenoport ship and switch thumbs. There's no crying in baseball and no loyalty in stocks, if you want to grow your brokerage account rather than watch helplessly as it gets shredded. I'm fortunately still in the win column with Xenoport with respect to real money at least, having done well on an impulsive purchase of calls right before Horizant approval.